A5077942901- Complement system in diseases
- Blood groups and transfusion
- Platelet Disorders and Treatments
- Neurotransmitter Receptor Influence on Behavior
- Neuroscience and Neuropharmacology Research
- T-cell and Retrovirus Studies
- Healthcare Quality and Management
- Chronic Lymphocytic Leukemia Research
- Primary Care and Health Outcomes
- Lymphoma Diagnosis and Treatment
- Neuroendocrine regulation and behavior
- DNA Repair Mechanisms
- Mesenchymal stem cell research
- Healthcare Policy and Management
- Tissue Engineering and Regenerative Medicine
- Topic Modeling
- Machine Learning in Materials Science
- DNA and Nucleic Acid Chemistry
- Receptor Mechanisms and Signaling
- Helicobacter pylori-related gastroenterology studies
- Viral-associated cancers and disorders
- Erythrocyte Function and Pathophysiology
- Cytomegalovirus and herpesvirus research
- Stress Responses and Cortisol
- Computability, Logic, AI Algorithms
University of Miami
2007-2023
SRI International
2011-2022
Menlo School
2019
Sylvester Comprehensive Cancer Center
1994-2017
Emmes (United States)
2012-2017
Tufts University
1992-2016
United States Air Force Research Laboratory
2015
University of Maryland, Baltimore
2014
Jackson Health System
2014
Johns Hopkins University
1997-2014
Mesenchymal stem cells (MSCs) are under evaluation as a therapy for ischemic cardiomyopathy (ICM). Both autologous and allogeneic MSC therapies possible; however, their safety efficacy have not been compared.To test whether MSCs safe effective in patients with left ventricular (LV) dysfunction due to ICM.A phase 1/2 randomized comparison (POSEIDON study) US tertiary-care referral hospital of 30 LV ICM between April 2, 2010, September 14, 2011, 13-month follow-up.Twenty million, 100 or 200...
Whether culture-expanded mesenchymal stem cells or whole bone marrow mononuclear are safe and effective in chronic ischemic cardiomyopathy is controversial.To demonstrate the safety of transendocardial cell injection with autologous (MSCs) (BMCs) patients cardiomyopathy.A phase 1 2 randomized, blinded, placebo-controlled study involving 65 left ventricular (LV) ejection fraction less than 50% (September 1, 2009-July 12, 2013). The compared MSCs (n=19) placebo (n = 11) BMCs 19) 10), year...
Background and objectives Although several standardized definitions for AKI have been developed, no consensus exists regarding which to use in children. This study applied the Pediatric RIFLE (pRIFLE), Network (AKIN), Kidney Disease Improving Global Outcomes (KDIGO) criteria an anonymized cohort of hospitalizations extracted from electronic medical record compare incidence outcomes intensive care unit (ICU) non-ICU pediatric populations. Design, setting, participants, & measurements...
Thrombotic thrombocytopenic purpura, the acute form of which is usually fatal, characterized clinically by thrombocytopenia, microangiopathic hemolytic anemia, fluctuating neurologic signs and renal dysfunction, pathologically diffuse thrombotic occlusions in microcirculation, platelets are consumed.1 2 3 4Since pathogenesis this disease not understood, treatment has been empirical or with an assumed rationale. Among various modes therapy tried, four especially advocated: splenectomy use...
Although accumulating data support the efficacy of intramyocardial cell-based therapy to improve left ventricular (LV) function in patients with chronic ischemic cardiomyopathy undergoing CABG, underlying mechanism and impact cell injection site remain controversial. Mesenchymal stem cells (MSCs) LV structure through several effects including reducing fibrosis, neoangiogenesis, neomyogenesis.To test hypothesis that on cardiac after injections autologous MSCs results from a concordance...
Although human mesenchymal stem cells (hMSCs) have been tested in ischemic cardiomyopathy, few studies exist chronic nonischemic dilated cardiomyopathy (NIDCM).The authors conducted a randomized comparison of safety and efficacy autologous (auto) versus allogeneic (allo) bone marrow-derived hMSCs NIDCM.Thirty-seven patients were to either allo- or auto-hMSCs 1:1 ratio. Patients recruited between December 2011 July 2015 at the University Miami Hospital. received (100 million) by...
Rationale: Cell dose and concentration play crucial roles in phenotypic responses to cell-based therapy for heart failure. Objective: To compare the safety efficacy of 2 doses allogeneic bone marrow–derived human mesenchymal stem cells identically delivered patients with ischemic cardiomyopathy. Methods Results: Thirty cardiomyopathy received a blinded manner either 20 million (n=15) or 100 via transendocardial injection (0.5 cc per × 10 injections patient). Patients were followed 12 months...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTA new mammalian DNA polymerase with 3' to 5' exonuclease activity: δJohn J. Byrnes, Kathleen M. Downey, Vicky L. Black, and Antero G. SoCite this: Biochemistry 1976, 15, 13, 2817–2823Publication Date (Print):June 29, 1976Publication History Published online1 May 2002Published inissue 29 June 1976https://doi.org/10.1021/bi00658a018RIGHTS & PERMISSIONSArticle Views190Altmetric-Citations167LEARN ABOUT THESE METRICSArticle Views are the...
We devised a method to enhance delivery of vinblastine macrophages, the cells believed be responsible for platelet destruction in idiopathic thrombocytopenic purpura. Our strategy was based on ability platelets bind vinca alkaloids such as vinblastine. Platelets were incubated with an excess vinblastine, concentrated and then, after alkaloid had been removed, given 11 patients thrombocytopenia refractory other treatment (including intravenous injections alkaloids). Platelet antibodies...
Aging frailty, characterized by decreased physical and immunological functioning, is associated with stem cell depletion. Human allogeneic mesenchymal cells (allo-hMSCs) exert immunomodulatory effects promote tissue repair. This a randomized, double-blinded, dose-finding study of intravenous allo-hMSCs (100 or 200-million [M]) vs placebo delivered to patients (n = 30, mean age 75.5 ± 7.3) frailty. The primary endpoint was incidence treatment-emergent serious adverse events (TE-SAEs) at...
Abstract Many patients with thrombotic thrombocytopenic purpura (TTP) satisfactorily respond to plasma therapy (plasmapheresis and/or infusion). Some, however, either not at all or only transiently and incompletely. Evidence indicates that platelets endothelial cell‐derived unusually large von Willebrand factor (ULvWF) multimers, as well the largest vWF multimers in plasma, form thrombi which are deposited microvascular circulation. Accordingly, platelet transfusions avoided unless there is...
Abstract An elderly patient with evidence of atherosclerosis and uremic bleeding diathesis developed two foci cerebral thrombosis immediately after an infusion desmopressin (DDAVP). Because large molecular weight multimers von Willebrand factor (vWF) have been demonstrated to cause platelet aggregation under conditions elevated fluid shear stress as occurs in atherosclerotic vessels, we investigated his plasma vWF at the time event compared it baseline values obtained 2 weeks later....
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTDNA polymerase .delta.: one polypeptide, two activitiesLee Pletts Goscin and John J. ByrnesCite this: Biochemistry 1982, 21, 10, 2513–2518Publication Date (Print):May 11, 1982Publication History Published online1 May 2002Published inissue 11 1982https://pubs.acs.org/doi/10.1021/bi00539a034https://doi.org/10.1021/bi00539a034research-articleACS PublicationsRequest reuse permissionsArticle Views122Altmetric-Citations74LEARN ABOUT THESE METRICSArticle...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTSelective inhibition of the 3' to 5' exonuclease activity associated with DNA polymerases: a mechanism mutagenesisJohn J. Byrnes, Kathleen M. Downey, Benito G. Que, Marietta Y. W. Lee, Vicky L. Black, and Antero SoCite this: Biochemistry 1977, 16, 17, 3740–3746Publication Date (Print):August 23, 1977Publication History Published online1 May 2002Published inissue 23 August...
Impaired endogenous stem cell repair capacity is hypothesized to be a biologic basis of frailty. Therapies that restore regenerative may therefore beneficial. This Phase 1 study evaluated the safety and potential efficacy intravenous, allogeneic, human mesenchymal (allo-hMSC)-based therapy in patients with aging In this nonrandomized, dose-escalation study, received single intravenous infusion allo-hMSCs: 20-million (n = 5), 100-million or 200-million cells 5). The primary endpoint was...